From Preclinical to Clinical – First-in-man Study
15:30-16:10 Speaker: Eliane Schutte
16:15-17:00 Speaker: Prof. Dr. Yigal Pinto
17:00-18:00 Networking drinks
Eliane Schutte is the CEO of Xeltis, a clinical-stage medtech company developing transformative implants that enable the natural creation of living and long-lasting vessels and valves. Xeltis aims to meet the needs of patients and healthcare providers by offering self-healing, non-immunogenic implants that remain open, with a low risk of infection and a reduced need for surgical reintervention. The company recently raised €44.5 million in a Series D2 round to fund its ongoing clinical development.
Eliane will speak about the challenges of entering clinical development from a young company’s perspective.
Prof. Dr. Yigal Pinto is a professor at the University of Amsterdam, where he leads the Department of Experimental Cardiology in conjunction with his clinical practice in heart failure. He has initiated and executed several prospective clinical trials on heart failure management. Based on 17 years of research within his group, Yigal founded Phlox Therapeutics, a preclinical-stage biotech company that develops RNA-based therapies for cardiac laminopathies and therapy-resistant heart failure. Yigal will reflect on the insights he has gained in preparing for clinical research, both from an investigator’s and a CMO’s perspective.
Register here: Registration form: RegMed XB & DCVA Community Event Nov 28